Indaptus Therapeutics, Inc. (INDP) Form 8-K — Sep 9, 2026
Indaptus Therapeutics entered into a Stock Purchase Agreement on September 8, 2026 to sell 20,338,974 shares of common stock in a private placement for approximately $24.0 million in gross proceeds, priced at the Nasdaq Minimum Price plus $0.015 per share (implying roughly $1.18 per share based on the stated deal size). Closing must occur no later than the 15th business day after signing, subject to Nasdaq listing approval for the new shares. The offering is exempt from registration under Section 4(a)(2) and Regulation S, sold to offshore purchasers who are each capped at 4.99% beneficial ownership post-closing and subject to a six-month Regulation S restricted period.
Key figures
- Gross Proceeds
- 24000000
- Offering Price
- Nasdaq Minimum Price plus $0.015 per share
- Shares Offered
- 20338974
- Shares Outstanding
- 133242324
- Closing Deadline
- no later than the 15th business day following September 8, 2026
- Dilution Percent
- approximately 15.3% of shares outstanding
- Warrants Outstanding
- 1788729
- Implied Per Share Price
- approximately $1.18 (derived from $24,000,000 / 20,338,974 shares)
- Purchaser Ownership Cap
- 4.99% of post-closing shares outstanding per purchaser
- Authorized Common Shares
- 1000000000
- Authorized Preferred Shares
- 5000000
- Regulation SRestricted Period
- six months from issuance
- Warrant Weighted Average Exercise Price
- 19.57
Price after filing
Close on the filing date to close N calendar days later (from $2.08). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.